

High Affinity Molecules Disrupting GRB2 Protein Complex Chronic Myelogenous Leukaemia

Leukemia and Lymphoma

44, 411-427

DOI: [10.1080/1042819021000037930](https://doi.org/10.1080/1042819021000037930)

Citation Report

#	ARTICLE	IF	CITATIONS
2	A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. <i>Biochemical and Biophysical Research Communications</i> , 2003, 310, 378-383.	1.0	35
3	Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3205-3208.	1.0	13
4	Animal models of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 525-543.	0.9	12
5	Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 4200-4208.	1.4	13
6	Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1385-1388.	1.0	13
7	Examination of Phosphoryl-Mimicking Functionalities within a Macrocyclic Grb2 SH2 Domain-Binding Platform. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3945-3948.	2.9	24
8	Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. <i>Gene</i> , 2006, 374, 26-38.	1.0	19
9	Facile synthesis and application of uniformly ¹³ C, ¹⁵ N-labeled phosphotyrosine for ligand binding studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3806-3808.	1.0	2
10	Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors. <i>Current Pharmaceutical Design</i> , 2006, 12, 529-548.	0.9	44
11	The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells. <i>Biochemical Pharmacology</i> , 2008, 75, 2080-2091.	2.0	17
12	Grb2 signaling in cell motility and cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1021-1033.	1.5	162
13	Tnk1/Kos1 Knockout Mice Develop Spontaneous Tumors. <i>Cancer Research</i> , 2008, 68, 8723-8732.	0.4	33
14	Distinct Binding Modes of Two Epitopes in Gab2 that Interact with the SH3C Domain of Grb2. <i>Structure</i> , 2009, 17, 809-822.	1.6	69
15	Grb2 and Other Adaptor Proteins in Tumor Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2010, , 77-102.	0.1	1
16	Inhibition of Grb2 expression demonstrates an important role in BCR/ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. <i>Leukemia</i> , 2011, 25, 305-312.	3.3	43
17	Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation. <i>Biochemical Pharmacology</i> , 2011, 81, 304-313.	2.0	30
18	Unusual binding of Grb2 protein to a bivalent polyproline-ligand immobilized on a SPR sensor: Intermolecular bivalent binding. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 524-535.	1.1	1
20	Insights into the Shc Family of Adaptor Proteins. <i>Journal of Molecular Signaling</i> , 2017, 12, 2.	0.5	34

#	ARTICLE	IF	CITATIONS
22	GRB2 Signaling as a Molecular Target for Cancer. , 2012, , 1-22.		1